TW202317514A - 新穎方法 - Google Patents

新穎方法 Download PDF

Info

Publication number
TW202317514A
TW202317514A TW111123528A TW111123528A TW202317514A TW 202317514 A TW202317514 A TW 202317514A TW 111123528 A TW111123528 A TW 111123528A TW 111123528 A TW111123528 A TW 111123528A TW 202317514 A TW202317514 A TW 202317514A
Authority
TW
Taiwan
Prior art keywords
piperidine
typically
solvent
group
protected
Prior art date
Application number
TW111123528A
Other languages
English (en)
Chinese (zh)
Inventor
保羅 弗瑞瑟
捷達 帕爾古納
瑪萊許 巴拉沙
喬瑟芬 E F 辛誇爾
瑞吉斯 J G 蒙迪爾
派洛 托莎蒂
Original Assignee
瑞士商F 霍夫曼拉羅氏股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商F 霍夫曼拉羅氏股份公司 filed Critical 瑞士商F 霍夫曼拉羅氏股份公司
Publication of TW202317514A publication Critical patent/TW202317514A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111123528A 2021-06-23 2022-06-23 新穎方法 TW202317514A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23
IN202141028180 2021-06-23

Publications (1)

Publication Number Publication Date
TW202317514A true TW202317514A (zh) 2023-05-01

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111123528A TW202317514A (zh) 2021-06-23 2022-06-23 新穎方法

Country Status (12)

Country Link
US (1) US20240150291A1 (enExample)
EP (1) EP4359385A2 (enExample)
JP (1) JP2024524215A (enExample)
KR (1) KR20240024842A (enExample)
CN (1) CN118019727A (enExample)
AR (1) AR126215A1 (enExample)
AU (1) AU2022300325A1 (enExample)
CA (1) CA3219597A1 (enExample)
IL (1) IL308071A (enExample)
MX (1) MX2023014547A (enExample)
TW (1) TW202317514A (enExample)
WO (1) WO2022268935A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876271B (zh) * 2022-02-15 2025-03-11 瑞士商赫孚孟拉羅股份公司 新穎方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024133610A1 (en) * 2022-12-23 2024-06-27 F. Hoffmann-La Roche Ag Proccesses for the preparation of an nlrp3 inhibitor
WO2025036914A1 (en) 2023-08-16 2025-02-20 F. Hoffmann-La Roche Ag Process for the preparation of preparing 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA917435B (en) * 1990-09-26 1992-05-27 Takeda Chemical Industries Ltd Herbicides
CA2059450A1 (en) * 1991-01-24 1992-07-25 Nobuyuki Sakashita Subsituted pyridinesulfonamide compound or its salt, process for preparing the same, and herbicide containing the same
JP2001518069A (ja) * 1997-05-02 2001-10-09 ドクター・レディーズ・リサーチ・ファウンデーション 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物
ATE342266T1 (de) * 2000-11-16 2006-11-15 Sankyo Co 1-methylcarbapenemderivate
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
MXPA04010172A (es) * 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
US7759387B2 (en) * 2003-10-08 2010-07-20 Piramal Life Sciences Limited Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
US8614215B2 (en) * 2007-02-22 2013-12-24 Merck Serono Sa Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks)
US20120196889A1 (en) * 2009-02-25 2012-08-02 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
EP3383853B1 (en) * 2015-12-01 2020-11-04 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease
KR102669722B1 (ko) * 2017-07-07 2024-05-29 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
SG11202001164SA (en) * 2017-08-15 2020-03-30 Inflazome Ltd Novel sulfonamide carboxamide compounds
KR20210018199A (ko) * 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
MA52489A (fr) * 2018-05-04 2021-03-10 Inflazome Ltd Nouveaux composés
CA3113573A1 (en) * 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof
CN111393415B (zh) * 2020-04-30 2020-11-20 苏州信诺维医药科技有限公司 一种杂芳腈类化合物及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876271B (zh) * 2022-02-15 2025-03-11 瑞士商赫孚孟拉羅股份公司 新穎方法

Also Published As

Publication number Publication date
AR126215A1 (es) 2023-09-27
US20240150291A1 (en) 2024-05-09
CN118019727A (zh) 2024-05-10
AU2022300325A8 (en) 2023-11-16
MX2023014547A (es) 2024-04-29
AU2022300325A1 (en) 2023-11-02
JP2024524215A (ja) 2024-07-05
WO2022268935A3 (en) 2023-02-02
KR20240024842A (ko) 2024-02-26
IL308071A (en) 2023-12-01
EP4359385A2 (en) 2024-05-01
CA3219597A1 (en) 2022-12-29
WO2022268935A2 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
AU2021212669B2 (en) GLP-1R modulating compounds
JP2025527298A (ja) 三環式化合物及びその医薬用途
TWI658042B (zh) 雜環化合物的合成
KR20240024842A (ko) Nlrp3 억제제의 제조 공정
TW202547822A (zh) 4-纈胺醯氧基丁酸的合成方法
KR20200057705A (ko) 리보시클립 및 그의 염의 제조를 위한 개선된 방법
JP2018521005A (ja) ウレア誘導体、またはその薬理学的に許容される塩
JP2024123202A (ja) 大環状化合物とその使用
WO2022214645A1 (en) Processes and intermediates for the preparation of relugolix
CN106220624A (zh) 阿哌沙班合成中的关键中间体和杂质:阿哌沙班二醇酯
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
TW202448866A (zh) 治療性化合物
US20240400516A1 (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivataives
HK1225388A1 (zh) 通过环化2-(氨基乙氧基)苯甲酸衍生物制备3,4-二氢-1,4-苯并氧氮杂环庚三烯-5(2h)-酮衍生物
WO2022094668A1 (en) Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
CA2648369A1 (en) Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
CN109748927A (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
HK40105889A (zh) 用於制备nlrp3抑制剂的方法
JP2026502847A (ja) Nlrp3阻害剤の調製のためのプロセス
JP2016172755A (ja) 抗ウイルス化合物およびその有用な中間体の調製方法
HK40116804A (en) Glp-1r modulating compounds
CN118234729A (zh) 用于制备双环甘氨酸-脯氨酸化合物和其单环甘氨酸-脯氨酸中间体的方法
HK40085187A (en) Glp-1r modulating compounds
HK40085187B (en) Glp-1r modulating compounds